named programs · 2 · from sources
what they call their work
Awareness and Advocacy
Participates in conferences and shares research breakthroughs to raise awareness about mitochondrial disease among the general population and healthcare professionals.
Research Funding
Supports cutting-edge research at the Translational Genomics Research Institute’s (TGen) Center for Rare Childhood Disorders in Phoenix, AZ, focusing on MTFMT-related Leigh syndrome.
activities · 2 groups
what they do
-
Gene Therapy Research for Rare Genetic Disorders 2 activities
- Funds and supports mitochondrial disease researchSupports research initiatives focused on understanding the genetic causes of mitochondrial disorders, including MTFMT-related Leigh Syndrome, through advanced genomic technologies, patient-derived iPSCs, and animal models. Collaborates with institutions such as TGen’s Center for Rare Childhood Disorders and supports specific projects like the development of a novel mouse model for MTFMT-related Leigh Syndrome.
- Supports research on mitochondrial disorders, including MTFMT-related Leigh SyndromeSupports research using genomic technologies, patient-derived iPSCs, and animal models to understand the genetic causes of mitochondrial disorders and identify potential treatments, with a focus on MTFMT-related Leigh Syndrome. Research is conducted in collaboration with institutions such as TGen’s Center for Rare Childhood Disorders and includes development of a novel mouse model for MTFMT-related Leigh Syndrome.
-
-
Uncategorized 2 activities
- Advocacy and scientific dissemination in mitochondrial diseaseEngages in scientific advocacy by presenting research findings at major mitochondrial medicine conferences, including the Mitochondrial Medicine Society and UMDF meetings, through oral presentations and posters focused on MTFMT mutations and disease mechanisms.
- Advocacy and scientific engagement in mitochondrial diseaseAdvances awareness of mitochondrial disease among healthcare professionals and the public through participation in scientific meetings, including the Mitochondrial Medicine Society and UMDF conferences. Presents research findings via oral presentations and posters, such as work on MTFMT splice site mutations and their therapeutic implications.
-
financials · form 990PF · fy2022
revenue
Total revenue$335
Contributions & grants$335100%
Program service revenue——
Investment income$00%
Other revenue—
expenses
Total expenses$183
Program expenses—
Admin / overhead—
Fundraising—
Salaries & benefits—
Grants paid out—
balance sheet
Total assets$832
Cash—
Investments—
Liabilities—
Net assets$732
4 years on record · 2019–2022 · YoY revenue +37.3%
leadership · form 990 part vii · fy2022
who runs it
board members · 2
- PHIL JOHNSON — DIRECTOR
- THOMAS JEFFERSON CESSNA IV — DIRECTOR
relationships · 5
who they work with
- ASU Partner — Supported undergraduate thesis work in 2022.
- Mitochondrial Medicine Society Partner — Participated in their Scientific and Clinical Meeting in 2022.
- Translational Genomics Research Institute Partner — Collaborated with Dr. Narayanan to enroll the Belnap family in a genetic study that used whole genome sequencing to identify a mutation in the MTFMT gene linked to Leigh syndrome.
- Translational Genomics Research Institute’s (TGen) Center for Rare Childhood Disorders Partner — Supports cutting-edge research at this institute.
- UMDF Partner — Presented at UMDF Mitochondrial Medicine 2022 and UMDF Mitochondrial Medicine Scientific and Clinical Meeting in 2019.